Results 121 to 130 of about 656,371 (370)

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.

Blood, 2018
The introduction of novel agents has led to major improvements in clinical outcomes for patients with multiple myeloma. To shorten evaluation times for new treatments, health agencies are currently examining minimal residual disease (MRD) as a surrogate ...
A. Perrot, V. Lauwers-Cances, J. Corre, N. Robillard, C. Hulin, M. Chrétien, T. Dejoie, S. Mahéo, A. Stoppa, B. Pégourié, L. Karlin, L. Garderet, B. Arnulf, C. Doyen, N. Meuleman, B. Royer, J. Eveillard, L. Benboubker, M. Dib, O. Decaux, A. Jaccard, K. Belhadj, S. Bréchignac, B. Kolb, C. Fohrer, M. Mohty, M. Macro, P. Richardson, V. Carlton, M. Moorhead, T. Willis, M. Faham, K. Anderson, J. Harousseau, X. Leleu, T. Facon, P. Moreau, M. Attal, H. Avet-Loiseau, N. Munshi   +39 more
semanticscholar   +1 more source

Mp-residuated lattices [PDF]

arXiv, 2022
This paper is devoted to the study of a fascinating class of residuated lattices, the so-called mp-residuated lattice, in which any prime filter contains a unique minimal prime filter. A combination of algebraic and topological methods is applied to obtain new and structural results on mp-residuated lattices.
arxiv  

Cellular liquid biopsy provides unique chances for disease monitoring, preclinical model generation and therapy adjustment in rare salivary gland cancer patients

Molecular Oncology, EarlyView.
We quantified and cultured circulating tumor cells (CTCs) of 62 patients with various cancer types and generated CTC‐derived tumoroid models from two salivary gland cancer patients. Cellular liquid biopsy‐derived information enabled molecular genetic assessment of systemic disease heterogeneity and functional testing for therapy selection in both ...
Nataša Stojanović Gužvić, Florian Lüke, Steffi Treitschke, Andrea Coluccio, Martin Hoffmann, Giancarlo Feliciello, Adithi Ravikumar Varadarajan, Xin Lu, Kathrin Weidele, Catherine Botteron, Silvia Materna–Reichelt, Felix Keil, Katja Evert, Florian Weber, Thomas Schamberger, Michael Althammer, Jirka Grosse, Dirk Hellwig, Christian Schulz, Stephan Seitz, Peter Ugocsai, Anke Schlenska‐Lange, Roman Mayr, Ulrich Kaiser, Wolfgang Dietmaier, Bernhard Polzer, Jens Warfsmann, Kamran Honarnejad, Tobias Pukrop, Daniel Heudobler, Christoph A. Klein, Christian Werno   +31 more
wiley   +1 more source

Molecular monitoring of minimal residual disease in two patients with MLL-rearranged acute myeloid leukemia and haploidentical transplantation after relapse [PDF]

, 2012
This report describes the clinical courses of two acute myeloid leukemia patients. Both had MLL translocations, the first a t(10;11)(p11.2;q23) with MLL-AF10 and the second a t(11;19)(q23;p13.1) with MLL-ELL fusion.
Beyer, Jörg, Blau, Igor Wolfgang, Burmeister, Thomas, Friedrichs, Birte, Lachmann, Nils, Lohm, Gunnar, Marschalek, Rolf, Meyer, Claus, Molkentin, Mara, Schwartz, Stefan, Tietze-Bürger, Carola, Uharek, Lutz   +11 more
core   +1 more source

Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

Leukemia, 2017
Flow cytometry has become a highly valuable method to monitor minimal residual disease (MRD) and evaluate the depth of complete response (CR) in bone marrow (BM) of multiple myeloma (MM) after therapy. However, current flow-MRD has lower sensitivity than
J. Flores-Montero, Luzalba Sanoja-Flores, B. Paiva, N. Puig, O. García-Sánchez, S. Böttcher, V. V. D. Velden, J. Perez-Moran, M. Vidriales, R. García-Sanz, Carmen Jiménez, Marcos González, J. Martínez-López, A. Corral-Mateos, G. Grigore, R. Fluxá, R. Pontes, J. Caetano, L. Sędek, M. C. Cañizo, J. Bladé, J. Lahuerta, C. Aguilar, A. Bárez, Aránzazu García-Mateo, J. Labrador, P. Leoz, C. Aguilera-Sanz, J. San-Miguel, M. Mateos, B. Durie, J. Dongen, J. Dongen, A. Órfão   +33 more
semanticscholar   +1 more source

Mass Spectrometry for Identification, Monitoring, and Minimal Residual Disease Detection of M-Proteins.

Clinical Chemistry, 2020
BACKGROUND Monoclonal gammopathies (MGs) are plasma cell disorders defined by the clonal expansion of plasma cells, resulting in the characteristic excretion of a monoclonal immunoglobulin (M-protein).
M. Zajec, P. Langerhorst, M. Vanduijn, J. Gloerich, H. Russcher, A. V. Gool, T. Luider, I. Joosten, Y. B. Rijke, J. Jacobs   +9 more
semanticscholar   +1 more source

Combined spatially resolved metabolomics and spatial transcriptomics reveal the mechanism of RACK1‐mediated fatty acid synthesis

Molecular Oncology, EarlyView.
The authors analyzed the spatial distributions of gene and metabolite profiles in cervical cancer through spatial transcriptomic and spatially resolved metabolomic techniques. Pivotal genes and metabolites within these cases were then identified and validated.
Lixiu Xu, Jinqiu Li, Junqi Ma, Ayshamgul Hasim   +3 more
wiley   +1 more source

Identification of residual leukemic cells by flow cytometry in childhood B-cell precursor acute lymphoblastic leukemia: verification of leukemic state by flow-sorting and molecular/cytogenetic methods

Haematologica, 2012
Reduction in minimal residual disease, measured by real-time quantitative PCR or flow cytometry, predicts prognosis in childhood B-cell precursor acute lymphoblastic leukemia.
Nina F. Øbro, Lars P. Ryder, Hans O. Madsen, Mette K. Andersen, Birgitte Lausen, Henrik Hasle, Kjeld Schmiegelow, Hanne V. Marquart   +7 more
doaj   +1 more source

Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis.

Blood Advances, 2020
Despite achieving a hematologic complete response after treatment, many patients with AL amyloidosis do not attain recovery of organ function and/or experience hematologic relapse.
Andrew Staron, Eric J Burks, John C. Lee, Shayna R Sarosiek, J. M. Sloan, V. Sanchorawala   +5 more
semanticscholar   +1 more source

Integrative systems‐level analysis reveals a contextual crosstalk between hypoxia and global metabolism in human breast tumors

Molecular Oncology, EarlyView.
Breast tumor samples scored for metabolic deregulation (M1 to M3) were given a hypoxia score (HS). The highest HS occurred in patients with strongest metabolic deregulation (M3), supporting tumor aggressiveness. HS correlated with the highest number of metabolic pathways in M1. This suggests hypoxia to be an early event in metabolic deregulation.
Raefa Abou Khouzam, Salem Chouaib, Mohammad Askandar Iqbal   +2 more
wiley   +1 more source